GO
| HSI1 | 23,094.83 | 0.00 | -- |
| HSCEI1 | 7,791.63 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-10-27 17:09:24 US stocks closed higher overnight (26th), with Anthropic's IPO filing reviving market sentiment and lifting chip and semiconductor stocks. Investors focused on this week's Federal Reserve rate decision and awaited announcements following the conclusion of the Fifth Plenary Session of the 20th CPC Central Committee. The HSI opened 48 pts higher this morning (27th) and once rose about 100 pts in early trading before selling pressure emerged. HSBC HOLDINGS (00005.HK) reported weaker-than-expected third-quarter results, dragging down the broader market. The HSI bottomed at 22,983 and closed at 23,041, down 170 pts or 0.73%, with turnover of HKD178.348 billion. The HSCEI closed at 7,766, down 35 pts or 0.45%. The HSTECH closed at 3,800, down 57 pts or 1.48%. Major tech stocks and heavyweight blue chips declined. HSBC HOLDINGS (00005.HK) fell 5.6% for the day after brokers said its third-quarter pre-provision profit missed expectations. MEITUAN-W (03690.HK) dropped 3%, BABA-W (09988.HK) fell 1%, TENCENT (00700.HK) declined 0.3%, KUAISHOU-W (01024.HK) slid 1.5%, NTES (09999.HK) lost 3.5%, BIDU-W (09888.HK) dropped 1.5%, and XIAOMI-W (01810.HK) tumbled 4.6%. CATL (03750.HK) fell 2.3% after Morgan Stanley downgraded the stock to Equalweight and slashed its TP by nearly 45%. Pharmaceutical and healthcare stocks generally moved lower. CSPC PHARMA (01093.HK) dropped 3.9%, HANSOH PHARMA (03692.HK) fell 3.2%, SBP GROUP (01177.HK) declined 3.1%, BEONE MEDICINES (06160.HK) lost 3%, WUXI BIO (02269.HK) dropped 2.7%, and WUXI APPTEC (02359.HK) still closed down 1.4% despite positive broker comments after results. INNOVENT BIO (01801.HK) also fell 2.4%, while SINOPHARM (01099.HK) rose 2.3%. In addition, BYD ELECTRONIC (00285.HK) dropped 2.7% and LI AUTO-W (02015.HK) fell 2.3%. CHINA RES LAND (01109.HK) declined 2.4%, while LONGFOR GROUP (00960.HK) slumped 7.1% to another record low. Chinese financial stocks rose against the broader market trend. CCB (00939.HK) gained 0.8% to close at HKD10, hitting a record high since listing. ICBC (01398.HK) rose 2.2% and CHINA LIFE (02628.HK) added 2.1%. Resource stocks performed well, with CHINA SHENHUA (01088.HK) up 2.4% and CMOC (03993.HK) rising 2.3%. LI NING (02331.HK) jumped 5.9% after brokers viewed its special dividend distribution as a positive surprise. LENOVO GROUP (00992.HK) rebounded 2.9%. AIA (01299.HK) gained 2.3%. CK ASSET (01113.HK) rose 2.4%, while CKI HOLDINGS (01038.HK) added 2.1%. Following Anthropic's IPO filing, AI-related and related hardware stocks showed mixed performance. Z.AI (02513.HK) surged 8.9%, while MINIMAX-W (00100.HK) retreated 1%. Some AI hardware stocks were boosted, with KB LAMINATES (01888.HK) and KINGBOARD HLDG (00148.HK) rising more than 3%. EASTROC (09980.HK) closed down 1.3%, while MENGNIU DAIRY (02319.HK) fell 2.5%, after both companies separately announced the end of their partnerships with French football star Kylian Mbappe. Among individual movers, CHINA TRAVEL HK (00308.HK) retreated 4.8% for the day, although Citi maintained a positive view on the company's spin-off of its Hong Kong and Macau cultural tourism business. YUE YUEN IND (00551.HK), which issued a profit warning, plunged 9.9%, while Goldman Sachs and Morgan Stanley said its third-quarter performance met expectations. SHIMAO GROUP (00813.HK), after plunging in the previous session, dropped another 8.9% today after its offshore debt instruments recently triggered a default involving more than USD9 billion in outstanding principal. DUALITYBIO-B (09606.HK) slumped 27.9%, with turnover surging to HKD790 million. The decline followed the company's announcement that the Phase III DYNASTY-BREAST02 clinical trial of pacmilimab trastuzumab had reached its primary endpoint, achieving a statistically significant moderate improvement in progression-free survival among patients with HR+/HER2-low metastatic breast cancer. However, data for the secondary endpoint of overall survival remained immature at the interim analysis stage. (ad/da)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |